Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vonoprazan + amoxicillin + Huazhi Rougan Granule
- Development stage
- Unknown
- Lead developer
- Nanjing First Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of vonoprazan, amoxicillin, and Huazhi Rougan Granule. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by competitively blocking the potassium-binding site of the H+,K+-ATPase enzyme. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Huazhi Rougan Granule is a Traditional Chinese Medicine (TCM) formulation used to treat metabolic-associated steatohepatitis (MASH), specifically targeting the dampness-heat accumulation syndrome. The combination is being evaluated by Nanjing First Hospital and Nanjing Medical University for its synergistic efficacy in eradicating Helicobacter pylori infection in patients who also suffer from MASH, aiming to improve both infection clearance and liver health.
- Other names
- Huazhi Rougan Granule combined with high-dose dual therapy
02
Targets
PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on vonoprazan + amoxicillin + Huazhi Rougan Granule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vonoprazan + amoxicillin + Huazhi Rougan Granule.